Ergoteles LLC Xencor Inc Transaction History

Ergoteles LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$25.95 - $36.95 $464,634 - $661,589	17,905 New	17,905 $499,000
Q3 2022 Nov 14, 2022	BUY	$24.62 - $32.44 $186,028 - $245,116	7,556 Added 44.31%	24,609 $639,000
Q2 2022 Aug 12, 2022	BUY	$19.74 - $29.01 $336,626 - $494,707	17,053 New	17,053 $467,000
Q3 2021 Nov 15, 2021	SELL	$30.65 - $35.68 $202,290 - $235,488	-6,600 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$34.33 - $44.68 $226,578 - $294,888	6,600 New	6,600 $228,000
Q1 2021 May 12, 2021	SELL	$40.81 - $53.88 $211,395 - $279,098	-5,180 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$36.63 - $47.63 $189,743 - $246,723	5,180 New	5,180 $226,000

215

71.5M

2.5K

7.9K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.44B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.